Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-787 in Adult Subjects With Acute Myeloid Leukemia (AML)

NCT06068868 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06068868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06068868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-787 in Adult Subjects With Acute Myeloid Leukemia (AML)
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
November 13, 2023
Completion date
February 25, 2025
Enrollment
36 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia